CRISPR’s New Tricks: DNA Guides Hit RNA With Near-Perfect Accuracy

CRISPR's New Tricks: DNA Guides Hit RNA With Near-Perfect Accuracy

The CRISPR field has spent a decade getting good at editing DNA. The central promise was permanent genomic surgery — cut out a bad gene, insert a good one, done. RNA editing has always been the harder problem. You are not fixing the original manual; you are correcting the working copies. The advantage is reversibility: edit an RNA transcript and the change fades when the cell makes a new one. The disadvantage has been that the tools for it have felt like workarounds.

A new platform from the University of Florida may have found a better answer. The system, called ΨDNA, is the first CRISPR platform to use DNA guides to target RNA rather than DNA. In patient samples, it detected hepatitis C virus RNA with 100% accuracy. That is not a promising early result. That is a number that makes diagnostics companies take a second look.

The work, published in Nature Biotechnology on May 15, comes from the lab of Piyush Jain, an associate professor of chemical engineering at the University of Florida. The problem he was trying to solve was practical. Existing RNA-targeting CRISPR systems, primarily those based on Cas13, tend to be chemically unstable, produce off-target effects, and are expensive to manufacture at scale. "You cannot easily edit RNA the way you edit DNA, and the existing tools have real limitations," Jain told GEN News. His team wanted something cheaper and more precise.

The core idea was counterintuitive. Every RNA-targeting CRISPR platform has used an RNA guide because that is how the machinery was designed. Jain asked a simpler question: what if you used a DNA guide instead?

The biochemistry was not straightforward. Simply swapping nucleobases produces a DNA strand that will not usefully engage an RNA target. The breakthrough was engineering a DNA guide that mimics the crRNA scaffold in reverse orientation, with a 3' DNA handle that triggers ribosome stalling and recruits RNase H1, an enzyme that specifically degrades RNA in RNA-DNA hybrids. The team used two nucleases: AsCas12a and Cas12i1. Both proved capable of binding the engineered DNA guide and executing knockdown.

The results were striking. In human cell lines, ΨDNA achieved 70 to 95% knockdown of endogenous RNA transcripts across multiple targets, competitive with existing RNA interference methods and, according to the authors, more specific. The 100% HCV detection figure came from a set of clinical samples tested at UF, a meaningful proof-of-concept requiring multi-center validation before commercial deployment. The exact sample size will need to be confirmed from the paper's supplementary materials.

The structural explanation came from cryo-EM work with David Taylor's group at the University of Texas at Austin. AsCas12a turned out to have more structural flexibility than the standard model predicted, allowing it to accommodate the DNA guide geometry. That structural insight gives the field a map for engineering the next generation of DNA-guide RNA editors.

The reversibility frame cuts both ways commercially. For patients, a transient RNA edit sounds safer than a permanent DNA change: if something goes wrong, you wait for the cell to make new transcripts and the error clears. For regulators, the calculus is less settled. Non-permanent interventions are a newer category and the long-term follow-up data does not exist at scale. For investors who have backed Cas13-based RNA editing pipelines, ΨDNA is an early-stage competitor that it would be premature to dismiss and premature to bet on.

The diagnostics angle is the near-term commercial play. Current HCV testing relies on PCR, which requires thermal cycling equipment, trained operators, and a laboratory. CRISPR-based detection can in principle run at room temperature on a paper strip. ΨDNA offers a potentially cheaper and more stable alternative because DNA is chemically more robust than RNA and easier to synthesize and store. If the 100% accuracy holds in larger studies, this is a viable path toward point-of-care HCV diagnostics in low-resource settings, where the disease burden is highest and the PCR infrastructure gap is widest.

If DNA guides prove as scalable as early data suggests, they could displace Cas13-based pipelines for RNA detection. That is a second-order risk for companies with existing RNA-detection investments that have not yet evaluated the ΨDNA architecture.

What distinguishes ΨDNA is the structural insight and the empirical demonstration that the DNA guide mechanism achieves high knockdown efficiency and perfect diagnostic accuracy in parallel. Making both cases together is unusual and suggests the authors recognized the dual commercial value of the finding.

The open questions are real. The engineered 3' DNA handle was the critical innovation, and it is not yet clear whether the approach generalizes to other Cas enzymes or target types. The 100% detection accuracy needs to be confirmed at larger scale and across multiple centers. The therapeutic applications are earlier still: cell line results are encouraging but the path to animal models and human trials is long and contingency-rich.

What is not in question is that the mechanism is real, structurally validated, and published in Nature Biotechnology. The RNA editing toolbox has a new tool in it. Whether it displaces Cas13 or finds its first commercial application in diagnostics will depend on the next round of data.

The paper, "DNA guide RNA enables programmable RNA targeting by Cas12 nucleases," appeared in Nature Biotechnology on May 15, 2026.